Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Oncosec Medical (ONCS)

Oncosec Medical (ONCS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 84,988
  • Shares Outstanding, K 23,032
  • Annual Sales, $ 0 K
  • Annual Income, $ -30,280 K
  • 60-Month Beta 2.40
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.86
Trade ONCS with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 07/31/20
See More
  • Average Estimate -0.10
  • Number of Estimates 1
  • High Estimate -0.10
  • Low Estimate -0.10
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.01%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.16 +8.54%
on 09/29/20
4.24 -19.10%
on 10/19/20
-0.39 (-10.21%)
since 09/25/20
3-Month
2.99 +14.72%
on 07/27/20
5.40 -36.48%
on 08/11/20
+0.24 (+7.52%)
since 07/24/20
52-Week
1.04 +230.13%
on 03/17/20
5.40 -36.48%
on 08/11/20
+1.14 (+49.78%)
since 10/25/19

Most Recent Stories

More News
OncoSec Announces Appointment of Sandra Aung, Ph.D. as Senior Vice President, Chief Clinical Development Officer

and , /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late- stage intra-tumoral cancer immunotherapies, today announced that , Ph.D. joined...

ONCS : 3.43 (-7.05%)
OncoSec Announces Issuance of New U.S. Patent Expanding Coverage of TAVO™ and Its Gene Delivery Platform

and , /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late- stage intratumoral cancer immunotherapies, today announced  the issuance of a...

ONCS : 3.43 (-7.05%)
OncoSec Announces Initiation of a Phase 2 Study at the Moffitt Cancer Center to Evaluate the Combination of TAVO plus OPDIVO® as Neoadjuvant Therapy for Melanoma

and , /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today announced the commencement of...

ONCS : 3.43 (-7.05%)
OncoSec to Present at the LD 500 Virtual Conference on September 2, 2020

and , /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today announced that , President and...

ONCS : 3.43 (-7.05%)
OncoSec Medical Incorporated Announces Pricing of Public Offering

and , /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec") today announced that in connection with its previously announced offering of common stock, it has entered...

ONCS : 3.43 (-7.05%)
OncoSec Medical Incorporated Announces Proposed Public Offering of Common Stock

and , /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec") today announced that it intends to offer and sell shares of its common stock in a public offering. The offering...

ONCS : 3.43 (-7.05%)
OncoSec to Present at the BTIG Virtual Biotechnology Conference 2020 on Tuesday, August 11, 2020

and , /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today announced that , President and...

ONCS : 3.43 (-7.05%)
OncoSec Set to Join Russel Microcap® Index

and , /PRNewswire/ -- (Nasdaq: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced the Company is set to join the Russell Microcap Index at the conclusion of the...

ONCS : 3.43 (-7.05%)
OncoSec Presents Two Late-Breaking Abstracts on TAVO-PLUS at the American Association for Cancer Research (AACR) Virtual Annual Meeting II

and , /PRNewswire/ --(Nasdaq: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today presented new data further demonstrating the power of OncoSec's next-generation interleukin-12...

ONCS : 3.43 (-7.05%)
OncoSec Expands KEYNOTE-890 Trial into First-Line Metastatic Triple Negative Breast Cancer (mTNBC) with TAVO™ and KEYTRUDA® Plus Chemotherapy

and , /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today announced that, based upon tumor...

MRK : 78.84 (-1.24%)
ONCS : 3.43 (-7.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

OncoSec Medical Incorporated is a biomedical company engaged in the designing, development and commercialization of therapeutic oncology products. It also develops novel OMS ElectroOncology therapies and OncoSec Medical System for the treatment of solid tumors. OncoSec Medical Incorporated is based in...

See More

Key Turning Points

2nd Resistance Point 3.84
1st Resistance Point 3.63
Last Price 3.43
1st Support Level 3.30
2nd Support Level 3.18

See More

52-Week High 5.40
Fibonacci 61.8% 3.73
Last Price 3.43
Fibonacci 50% 3.22
Fibonacci 38.2% 2.70
52-Week Low 1.04

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar